학술논문
402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S350-S351
Subject
Language
ISSN
0923-7534